OR WAIT null SECS
The company expanded its UK storage facility to meet increasing demand from its growing customer base.
Intertek announced on May 22, 2017 the further expansion of its good manufacturing practice (GMP) pharmaceutical stability storage facility in the United Kingdom to a capacity of 250,000 liters. The 10,000-square-foot facility, based in Royston, was launched in May 2015 to broaden the range of solutions Intertek can offer to the global pharmaceutical industry. Since the opening of this facility, a growing number of clients across the pharmaceutical industry and other sectors such as medical devices, cosmetics, specialty chemicals, and consumer healthcare, have expressed a need for increased stability storage. The expanded facility enables Intertek to offer a wider range of bespoke storage conditions alongside the typical International Council for Harmonization (ICH) conditions.
The expansion was also made in response to increased demand for disaster recovery storage, contingency storage programs, and “storage-only” projects where a GMP outsourcing partner is required to help mitigate risks associated with the lifecycle of pharmaceutical products. These risks include potential loss of valuable products that have been in stability storage for a number of years, disruption to the continuation and integrity of the stability trial, and disruption to operations, downtime, and productivity.
GMP stability testing forms a key part of Intertek’s pharmaceutical development services. Intertek’s global ICH stability storage and testing locations also include Manchester (UK), Whitehouse (New Jersey, US), and Melbourne (Australia). Intertek has been providing cGMP contract analytical, bioanalytical, stability, and formulation support, as well as regulatory affairs services for 20 years.